Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...

Full description

Bibliographic Details
Main Authors: Yusuke Funakoshi, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Kosuke Takigawa, Masahiro Mizoguchi
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Pharmaceuticals
Subjects:
bevacizumab
glioblastoma
vascular endothelial growth factor (VEGF)
chemotherapy
survival
Online Access:https://www.mdpi.com/1424-8247/13/12/470

Internet

https://www.mdpi.com/1424-8247/13/12/470

Similar Items